Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Next Science Ltd ( (AU:NXS) ) has provided an announcement.
Next Science Limited has announced that it will release its financial results for the fiscal year ending December 31, 2024, on February 28, 2025. The release will be followed by a webinar hosted by CEO I.V. Hall and CFO Marc Zimmerman, aimed at engaging with the investment community. This announcement highlights the company’s transparency and engagement with stakeholders, potentially influencing investor confidence and market perception.
More about Next Science Ltd
Next Science is a medical technology company based in Sydney, Australia, with a research and development center in Florida, USA. Founded in 2012, the company focuses on developing and commercializing its proprietary XBIO™ technology, which targets biofilm-based infections in human health. This non-toxic technology effectively eradicates both biofilm-based and free-floating bacteria, and is fully owned and patent protected by Next Science.
YTD Price Performance: 28.57%
Average Trading Volume: 19,996
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $21.97M
For an in-depth examination of NXS stock, go to TipRanks’ Stock Analysis page.
